Please provide your email address to receive an email when new articles are posted on . Both phase 3b studies met their primary endpoints of improved frown lines and crow’s feet. A majority of ...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma announced today topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (GL – frown lines) and ...
Please provide your email address to receive an email when new articles are posted on . When treated separately, 71% of patients treated for frown lines and 45% treated for crow’s feet saw ...
NEWPORT BEACH, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results